Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners

Alliance Global Partners analyst James Molloy lowered the firm’s price target on Aquestive Therapeutics (AQST) to $4.75 from $5.50 and keeps a Buy rating on the shares. Aquestive recently highlighted their upcoming catalysts, including the new drug application filing for Anaphylm Sublingual Film formulated for the emergency treatment of severe allergic reactions, including anaphylaxis, the firm says, adding that it has lower confidence in Aquestive’s ability to maximize the Anaphylm franchise should it receive approval. The firm is valuing Anaphylm for anaphylaxis at $3/share and Libervant for pediatric epilepsy at 25c/share.